Audrey Sternberg | Authors


Pembrolizumab and Chemotherapy Combo Emerges for Patients With TNBC

December 31, 2020

Earlier in the year, Javier Cortes, MD, PhD, presented progression-free survival results from the phase 3 KEYNOTE-355 clinical trial, which showed the importance of the addition of taxanes to a platinum-based regimen in the triple-negative breast cancer space.

Venetoclax Makes Inroads Into More Hematologic Setting

December 30, 2020

Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 inhibitor venetoclax garnered attention in 2020 for positive reports from phase 3 clinical trials exploring its use in acute myeloid leukemia and multiple myeloma.

CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy Indications

December 26, 2020

Multiple chimeric antigen receptor T-cell therapies for the treatment of lymphomas and multiple myeloma have moved forward in the regulatory process, with 1 new FDA approval in 2020 and others anticipated in the near future.